Key Study Summaries

What are the key study summaries?

In every speciality there  are studies that shape the way how we mange certain conditions; these studies are called key studies. Knowledge of and understanding the key studies, as well as critically appraising them, is key to safe and successful management. We launched the key study summaries project with the aim to bring all the important studies in gynaecology to one place and make it easily accessible no matter where you are. 

We are always looking for authors  to contribute in the key study summaries and other projects. If you wish to submit your contribution please follow the link. We look forward hearing from you. 

Cervical cancer

Cervical Cancer
LACC Study

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical cancer

Cervical Cancer
GOG-120 Study

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Cervical Cancer
GOG-240 Study

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Bulky stage IB cervical carcinoma May/1999

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy

Bulky stage IB cervical carcinoma April/1999

Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

High-Risk Early-Stage Cancer of the Cervix GOG109

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix.

Cervical Cancer (GOG 92)

To determine whether postoperative pelvic radiotherapy following radical hysterectomy and pelvic node dissection would reduce the rate of reoccurrence and decrease mortality in Stage IB cancer patients.

Ovarian cancer

Ovarian Cancer
ICON1 Study

International Collaborative Ovarian Neoplasm Trial 1

Ovarian Cancer
CHORUS Study

Neoadjuvant Chemotherapy/Interval Debulking Surgery Vs Primary Debulking Surgery in Advanced Ovarian Cancer

Ovarian Cancer
EORTC55971 Study

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Advanced ovarian CA (MITO-7)

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7)

Advanced Ovarian Cancer (GOG-178)

Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients with Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy

Ovarian Cancer

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

HIPEC in Ovarian Cancer

To investigate whether the addition of (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial cancer

Ovarian Cancer
ACTION Trial

Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma

Ovarian cancer ICON7 study

A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The study question was to investigate the addition of bevacizumab to standard chemotherapy in the first-line treatment of ovarian cancer.

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer GOG172

The study question was to test the effectiveness of intraperitoneal Cisplatin and Paclitaxel in addition to intravenous Paclitaxel in women with stage III ovarian cancer who had optimal debulking surgery.

Ovarian Cancer (GOG 182)

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer

Ovarian Cancer (PAOLA-1)

Assessing the effects of Olaparib in combination with bevacizumab on disease progression as first-line maintenance in Ovarian Cancer

uterine cancer

Uterine Cancer
LACE Study

Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer

Endometrial carcinoma GOG 122

Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

Uterine Cancer
LAP2 Study

Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2

Uterine Cancer
PORTEC-1 Study

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multi-centre randomised trial

Uterine Cancer
ASTEC Study

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

Intermediate- and high-risk endometrial cancer JGOG 2008​

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer JGOG 2008

Advanced Endometrial Cancer GOG258

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer (GOG258). The study question was to evaluate the use of chemoradiotherapy as compared with the use of chemotherapy alone in locally advanced endometrial cancer.

Endometrial Cancer (GOG 249)

To determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival compared with pelvic radiation therapy (RT) in high-risk early-stage endometrial carcinoma

vulvar cancer

Vulvar Cancer
SNL Study 2008

Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer

Vulvar Cancer
GOG 173

Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study

gestational trophoblastic neoplasia

Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia (GOG 242)

To define the efficacy and safety of second curettage in patients with persistent, nonmetastatic low-risk GTN

Low-Risk Gestational Trophoblastic Neoplasia

Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study

What You Get

  • Your contribution will  help large number of gynaecologists who visit our website do a better job .
  • Being one of our authors will help promote your academic and writing skills.
  • We will help you promote your publications through our social media presence.
  • Being part of “GynaeFellow” family will enable you to gain contacts which may enable you to advance your career.